IMMUNOVANT INC. - CO

Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024

07 Nov 2024 05:30:00 By Nasdaq GlobeNewswire

Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves’ Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting

29 Oct 2024 05:30:00 By Nasdaq GlobeNewswire

Immunovant Provides Update on Graves’ Disease Development Program

09 Sep 2024 02:55:00 By Nasdaq GlobeNewswire

Immunovant to Host Graves’ Disease Program Update on September 9, 2024

05 Sep 2024 05:30:00 By Nasdaq GlobeNewswire

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2024

06 Aug 2024 15:05:01 By Nasdaq GlobeNewswire

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024

29 May 2024 15:01:00 By Nasdaq GlobeNewswire

Immunovant Awarded U.S. Patent for IMVT-1402

12 Mar 2024 06:30:04 By Nasdaq GlobeNewswire

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023

12 Feb 2024 06:00:00 By Nasdaq GlobeNewswire

Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare Conference

03 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease

20 Dec 2023 15:30:00 By Nasdaq GlobeNewswire

Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential

28 Nov 2023 06:00:00 By Nasdaq GlobeNewswire

Immunovant to Present at Upcoming Investor Conferences

13 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended September 30, 2023

09 Nov 2023 06:00:00 By Nasdaq GlobeNewswire

Immunovant Announces Closing of Upsized Common Stock Financing and Full Exercise of Underwriters’ Option to Purchase Additional Shares

02 Oct 2023 15:52:02 By Nasdaq GlobeNewswire

Immunovant Announces Pricing of $450 Million Common Stock Financing

27 Sep 2023 22:41:51 By Nasdaq GlobeNewswire

Immunovant Announces Proposed Offering of $300 Million of Common Stock

26 Sep 2023 16:00:00 By Nasdaq GlobeNewswire

Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results

26 Sep 2023 05:00:00 By Nasdaq GlobeNewswire

Immunovant to Host Conference Call and Webcast to Report Initial IMVT-1402 Phase 1 Results on September 26, 2023

25 Sep 2023 22:01:32 By Nasdaq GlobeNewswire

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2023

10 Aug 2023 06:00:01 By Nasdaq GlobeNewswire

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023

22 May 2023 06:00:00 By Nasdaq GlobeNewswire